±ÙÄ¡Àû À§ÀýÁ¦¼úÀ» ½ÃÇàÇÑ À§¾Ï ȯÀÚ¿¡¼ º¸Á¶¿ä¹ýÀ¸·Î¼ 5-Fluorouracil. Epirubicin°ú 5 Fluorouracil. CisplatinÀÇ º¹ÇÕ ÈÇпä¹ýÀÇ È¿°úºñ±³
A Randomized Trial Comparing 5-Fluorouracil and Epirubicin to 5-Flouourcil and Cisplatin as adjucant chemotherapy in Operable Gastric Cancer
ÇѾçÀÇ´ëÇмúÁö 2000³â 20±Ç 2È£ p.67 ~ p.73
ÃÖÁ¤Çý(Choi Jung-Hye) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¾È¸íÁÖ(Ahn Myung-Ju) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Çѵ¿¼ö(Han Dong-Soo) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¼ÕÁÖÇö(Sohn Joo-Hyun) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Àü¿ëö(Jeon Yong-Chul) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚÈÍ°â(Park Hwon-Kyum) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¹éÈ«±Ô(Baik Hong-Kyu) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Abstract
To compare 5-fluorouracil plus epirubicin (FE) to 5-fluorouracil plus cisplatin (FP) chemotherapy as adjuvant therapy for patients with resected gastric cancer.
Between August 1995 and March 2000, 46 patients with completely resected gastric cancer received six courses of FE (5-fluorouracil 1000mg/m2/day, D2-D5, epirubicin 70mg/m2, D1) or FP (5-fluorouracil 1000mg/m2/day, D2-D5, cisplatin 70 mg/m2, D1) chemotherapy. The 23 patients were assigned to each treatment group. A total of 127 courses of treatment were given both FE and FP group. The FP group tended to show more risk of overall death rate. But there were no differences between FE and FP groups in terms of overall survival or disease-free survival. Both treatment arms were generally well tolerated to chemotherapy.
We concluded to be no significant differences between FE and FP groups in terms of overall survival or disease-free survival. To define the efficacy of adjuvant chemotherapy for gastric adenocarcinoma, further prospective randomized trials with large number of patients should be warranted.
Å°¿öµå
gastric cancer, adjuvant chemotherapy, 5-fluorouracil, epirubicin, cisplatin
KMID :
0382620000200020067
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
This study reported no significant differences between FE and FP groups in terms of overall survival or disease-free survival.